Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 15 studies | 23% ± 8% | |
| type I pneumocyte | 12 studies | 33% ± 11% | |
| type II pneumocyte | 12 studies | 27% ± 11% | |
| epithelial cell | 8 studies | 38% ± 18% | |
| basal cell | 6 studies | 33% ± 11% | |
| ciliated cell | 6 studies | 25% ± 9% | |
| respiratory goblet cell | 5 studies | 22% ± 5% | |
| secretory cell | 5 studies | 23% ± 8% | |
| club cell | 5 studies | 31% ± 9% | |
| fibroblast | 5 studies | 21% ± 5% | |
| monocyte | 4 studies | 18% ± 2% | |
| squamous epithelial cell | 4 studies | 74% ± 15% | |
| classical monocyte | 4 studies | 21% ± 5% | |
| mast cell | 4 studies | 42% ± 11% | |
| myeloid cell | 3 studies | 19% ± 2% | |
| capillary endothelial cell | 3 studies | 17% ± 2% | |
| macrophage | 3 studies | 20% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 5 studies | 24% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 100% | 15233.31 | 327 / 328 | 100% | 294.83 | 178 / 178 |
| prostate | 100% | 13229.76 | 245 / 245 | 99% | 216.57 | 499 / 502 |
| stomach | 100% | 12797.30 | 359 / 359 | 99% | 189.59 | 284 / 286 |
| esophagus | 100% | 42711.67 | 1442 / 1445 | 99% | 320.82 | 182 / 183 |
| lung | 100% | 23874.49 | 578 / 578 | 99% | 250.56 | 1143 / 1155 |
| uterus | 99% | 7747.34 | 169 / 170 | 99% | 302.22 | 456 / 459 |
| intestine | 100% | 12304.94 | 965 / 966 | 99% | 224.40 | 521 / 527 |
| skin | 100% | 23735.47 | 1809 / 1809 | 99% | 262.03 | 466 / 472 |
| bladder | 100% | 13088.71 | 21 / 21 | 98% | 251.16 | 493 / 504 |
| breast | 98% | 8551.80 | 451 / 459 | 99% | 171.61 | 1102 / 1118 |
| thymus | 100% | 22862.38 | 653 / 653 | 94% | 286.28 | 568 / 605 |
| ovary | 94% | 5606.57 | 169 / 180 | 96% | 149.41 | 413 / 430 |
| kidney | 92% | 8425.61 | 82 / 89 | 97% | 140.90 | 871 / 901 |
| adrenal gland | 100% | 19322.31 | 258 / 258 | 84% | 91.37 | 193 / 230 |
| brain | 51% | 2285.94 | 1339 / 2642 | 92% | 83.94 | 647 / 705 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 411.42 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 169.51 | 1 / 1 |
| blood vessel | 100% | 14632.15 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 98% | 8523.26 | 1174 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 98% | 127.27 | 78 / 80 |
| spleen | 93% | 5900.95 | 223 / 241 | 0% | 0 | 0 / 0 |
| heart | 79% | 4237.24 | 677 / 861 | 0% | 0 | 0 / 0 |
| liver | 11% | 551.21 | 25 / 226 | 38% | 43.95 | 154 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 24% | 14.69 | 7 / 29 |
| peripheral blood | 20% | 952.17 | 189 / 929 | 0% | 0 | 0 / 0 |
| muscle | 7% | 290.60 | 56 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_2000679 | Biological process | positive regulation of transcription regulatory region DNA binding |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0032274 | Biological process | gonadotropin secretion |
| GO_0030948 | Biological process | negative regulation of vascular endothelial growth factor receptor signaling pathway |
| GO_0016525 | Biological process | negative regulation of angiogenesis |
| GO_0040019 | Biological process | positive regulation of embryonic development |
| GO_0043066 | Biological process | negative regulation of apoptotic process |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0030154 | Biological process | cell differentiation |
| GO_0044029 | Biological process | positive regulation of gene expression via chromosomal CpG island demethylation |
| GO_2000279 | Biological process | negative regulation of DNA biosynthetic process |
| GO_0045746 | Biological process | negative regulation of Notch signaling pathway |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0048743 | Biological process | positive regulation of skeletal muscle fiber development |
| GO_0007411 | Biological process | axon guidance |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005912 | Cellular component | adherens junction |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0045296 | Molecular function | cadherin binding |
| GO_0003713 | Molecular function | transcription coactivator activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | NIBAN2 |
| Protein name | Protein Niban 2 (Meg-3) (Melanoma invasion by ERK) (MINERVA) (Niban-like protein 1) (Protein FAM129B) FAM129B protein |
| Synonyms | FAM129B C9orf88 |
| Description | FUNCTION: May play a role in apoptosis suppression. May promote melanoma cell invasion in vitro. . |
| Accessions | Q96TA1 ENST00000373314.7 [Q96TA1-2] ENST00000373312.4 [Q96TA1-1] Q2YD88 |